Compass Therapeutics (CMPX) Other Accumulated Expenses (2019 - 2026)

Compass Therapeutics (CMPX) has 8 years of Other Accumulated Expenses data on file, last reported at $708000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 158.39% year-over-year to $708000.0; the trailing twelve-month figure through Mar 2026 stood at $708000.0 (up 158.39% YoY), and the FY2025 full-year result was $484000.0, down 22.06% from the prior year.
• Other Accumulated Expenses improved to $708000.0 in Q1 2026, from $484000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $1.5 million in Q1 2022 to a low of $88000.0 in Q3 2022.
• A 5-year average of $372470.6 and a median of $281000.0 in 2024 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses jumped 481.35% in 2022 and tumbled 90.65% in 2023, its largest moves.
• Tracing CMPX's Other Accumulated Expenses over 5 years: stood at $96000.0 in 2022, then soared by 150.0% to $240000.0 in 2023, then jumped by 158.75% to $621000.0 in 2024, then retreated by 22.06% to $484000.0 in 2025, then surged by 46.28% to $708000.0 in 2026.
• Business Quant data shows CMPX's Other Accumulated Expenses at $708000.0 in Q1 2026, $484000.0 in Q4 2025, and $141000.0 in Q3 2025.